Jiangsu Dongbuzhou Science and Technology Park Group

Jiangsu Dongbuzhou Science and Technology Park Group

Jiangsu Dongbuzhou Science and Technology Park Group was established in 2013 as the primary development and investment vehicle for the Linjiang New Area in Haimen District, Nantong. The group is wholly owned by Jiangsu Haihong Investment Holding Group and ultimately controlled by the Haimen District State-owned Assets Supervision and Administration Commission (SASAC). Its creation reflects a familiar Chinese municipal model: a dedicated SOE that builds the hard infrastructure — roads, utilities, commercial buildings — and then uses its balance sheet to attract and anchor private-sector tenants through equity co-investments and subsidized leasing. The group's mandate spans three operational layers. On the real-asset side, it owns and operates Linjiang New Area infrastructure projects and a portfolio of science-and-technology park leasing assets in Haimen, making it the district's largest industrial landlord. On the investment side, it takes direct equity stakes in companies that locate within the park, functioning as a captive corporate venture arm. A publicly recorded example is its co-investment in Haimen Hechuang Animal Experiment Technology Co., Ltd., a joint venture with Biocytogen Pharmaceuticals — a Beijing-based biotech firm listed on the Shanghai Stock Exchange. This deal illustrates a pattern: JDBZ provides real estate and local operating support, while the corporate partner brings IP and national market access. Geographically, all known activity is concentrated within Jiangsu province, specifically the Nantong-Haimen corridor, though the group's parent structure suggests capacity for capital deployment across the Yangtze River Delta. As a district-level SOE, JDBZ does not publicly report assets under management or total investment deployment. Its balance sheet is consolidated within the Haimen SASAC reporting entity, and no external rating agency has published a standalone credit assessment. The group's paid-in capital is denominated in renminbi and reflects municipal fiscal allocations rather than third-party fundraising — it is not a fund manager and does not raise blind-pool capital. In 2024, the group continued to market its science park as a destination for pharmaceutical and advanced-manufacturing tenants, consistent with Jiangsu province's broader industrial policy push into biotech and new materials (per provincial development zone registries). Jiangsu Dongbuzhou's structural differentiator is its identity as a pure district-government operating company without any private family-office overlay or diversified LP base. Unlike the hybrid state-family offices seen in Zhejiang or Guangdong, JDBZ has no disclosed ultra-high-net-worth principals and no investment committee independent of the SASAC reporting line. This makes it a direct instrument of municipal industrial policy — its investment decisions are land-use grants and zoning concessions as much as equity checks. For an external GP or co-investor, engaging JDBZ means negotiating with the district government itself, which can collapse timelines but also introduces the full compliance burden of China's state-asset regulatory framework.